HPV DNA testing in cervical cancer screening - Results from women in a high-risk province of Costa Rica

被引:411
|
作者
Schiffman, M
Herrero, R
Hildesheim, A
Sherman, ME
Bratti, M
Wacholder, S
Alfaro, M
Hutchinson, M
Morales, J
Greenberg, MD
Lorincz, AT
机构
[1] NCI, Interdisciplinary Studies Sect, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA
[2] Int Agcy Res Canc, F-69372 Lyon, France
[3] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[4] Costa Rican Social Secur Adm, San Jose, Costa Rica
[5] Brown Univ, Women & Infants Hosp, Providence, RI USA
[6] Omnia, Blue Bell, PA USA
[7] Digene Corp, Silver Spring, MD USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 283卷 / 01期
关键词
D O I
10.1001/jama.283.1.87
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Human papillomaviruses (HPVs) are known to cause most cervical cancer worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not been determined. Objective To provide comprehensive data on the screening performance of HPV testing for the most common carcinogenic types, at different levels of analytic sensitivity. Design Laboratory analysis conducted during 1993-1995, using 3 cytologic techniques and cervicography, followed by colposcopic examination of women with any abnormal cervical finding, to detect all high-grade intraepithelial lesions and cancer (reference standard of clinically significant disease). The HPV testing was performed subsequently with masking regarding clinical findings. Setting Guanacaste Province, Costa Rica, a region with a high age-adjusted incidence of cervical cancer. Participants Of 11742 randomly selected women, 8554 nonpregnant, sexually active women without hysterectomies underwent initial HPV DNA testing using the original Hybrid Capture Tube test; a stratified subsample of 1119 specimens was retested using the more analytically sensitive second generation assay, the Hybrid Capture II test. Main Outcome Measures Receiver operating characteristic analysis of detection of cervical high-grade intraepithelial lesions and cancer by HPV DNA testing based on different cut points of positivity. Results An analytic sensitivity of 1.0 pg/mL using the second generation assay would have permitted detection of 88.4% of 138 high-grade lesions and cancers (all 12 cancers were HPV-positive), with colposcopic referral of 12.3% of women. Papanicolaou testing using atypical squamous cells of undetermined significance as a cut point for referral resulted in 77.7% sensitivity and 94.2% specificity, with 6.9% referred. Specificity of the second generation assay for positivity for high-grade lesions and cancer was 89.0%, with 33.8% of remaining HPV DNA-positive subjects having low-grade or equivocal microscopically evident lesions. The higher detection threshold of 10 pg/mL used with the original assay had a sensitivity of 74.8% and a specificity of 93.4%, Lower levels of detection with the second generation assay (<1 pg/mL) proved clinically nonspecific without gains in diagnostic sensitivity, Conclusions In this study population, a cut point of 1.0 pg/mL using the second generation assay permitted sensitive detection of cervical high-grade lesions and cancer, yielding an apparently optimal trade-off between high sensitivity and reasonable specificity for this test. The test will perform best in settings in which sensitive detection of high-grade lesions and cancer is paramount. Because HPV prevalence varies by population, HPV testing positive predictive value for detection of high-grade lesions and cancer will vary accordingly, with implications for utility relative to other cervical cancer screening methods.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [41] Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening
    Chung, Hae-Sun
    Hahm, Chorong
    Lee, Miae
    JOURNAL OF VIROLOGICAL METHODS, 2014, 205 : 57 - 60
  • [42] High-risk Human Papillomavirus Testing for Cervical Cancer Screening-Reply
    Dang, Le
    Qiao, Youlin
    Lang, Jinghe
    JAMA ONCOLOGY, 2021, 7 (07) : 1067 - 1068
  • [43] Management of high-risk HPV-positive women for detection of cervical (pre)cancer
    Luttmer, Roosmarijn
    De Strooper, Lise M. A.
    Steenbergen, Renske D. M.
    Berkhof, Johannes
    Snijders, Peter J. F.
    Heideman, Danielle A. M.
    Meijer, Chris J. L. M.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (09) : 961 - 974
  • [44] Accuracy of high-risk HPV DNA detection from urine and cervical samples in abnormal pap smear women
    Achariyapota, V.
    Punyashthira, A.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 38 - 39
  • [45] PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears
    Rozendaal, L
    Walboomers, JMM
    vanderLinden, JC
    Voorhorst, FJ
    Kenemans, P
    Helmerhorst, TJM
    vanBallegooijen, M
    Meuer, CJLM
    INTERNATIONAL JOURNAL OF CANCER, 1996, 68 (06) : 766 - 769
  • [46] Guidelines for HPV-DNA Testing for Cervical Cancer Screening in Brazil
    Zeferino, Luiz Carlos
    Bastos, Joana Braganca
    Andrade Peixoto do Vale, Diama Bhadra
    Zanine, Rita Maria
    Mendes Furtado de Melo, Yara Lucia
    Salles Pereira Primo, Walquiria Quida
    Correa, Flavia de Miranda
    Chulvis do Val, Isabel Cristina
    Russomano, Fabio
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2018, 40 (06): : 360 - 368
  • [47] Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy
    Schneider, A
    Hoyer, H
    Lotz, B
    Leistritz, S
    Kühne-Heid, R
    Nindl, I
    Müller, B
    Haerting, J
    Durst, M
    INTERNATIONAL JOURNAL OF CANCER, 2000, 89 (06) : 529 - 534
  • [48] The clinical utility of HPV DNA testing in cervical cancer screening strategies
    Bhatla, Neerja
    Moda, Nidhi
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2009, 130 (03) : 261 - 265
  • [49] Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China
    Xu, Huihui
    Lin, Aifen
    Shao, Xiujuan
    Shi, Weiwu
    Zhang, Yang
    Yan, Weihua
    ONCOTARGET, 2016, 7 (50) : 83775 - 83783
  • [50] Barriers to cervical screening participation in high-risk women
    Lovell B.
    Wetherell M.A.
    Shepherd L.
    Journal of Public Health, 2015, 23 (1) : 57 - 61